Evaluation of the Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis

Background: Poly(ADP-ribose) polymerase (PARP) inhibitors have breakthrough designations for metastatic castration-resistant prostate cancer (mCRPC). We performed a meta-analysis of current clinical trials to evaluate the efficacy of PARP inhibitors in mCRPC patients based on their genetic status. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Kan, Liang, Jiayu, Shao, Yanxiang, Xiong, Sanchao, Feng, Shuyang, Li, Xiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718674/
https://www.ncbi.nlm.nih.gov/pubmed/34975480
http://dx.doi.org/10.3389/fphar.2021.777663

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718674/
https://www.ncbi.nlm.nih.gov/pubmed/34975480
http://dx.doi.org/10.3389/fphar.2021.777663

Ejemplares similares